A Phase 3 study evaluating liraglutide for obesity in children, known as SCALE KIDS (NCT04775082), reached its primary completion on 2023-08-01. This trial enrolled 78 participants to investigate the drug's effect on body weight in this population.
Background
Liraglutide is currently approved and prescribed for adults with overweight or obesity. The SCALE KIDS study investigates its potential as a new treatment option for children diagnosed with obesity, building on its established use in adult populations.
Trial design
The Phase 3 SCALE KIDS study (NCT04775082) enrolled 78 participants with obesity. The trial was designed to assess how liraglutide works on participants' body weight, specifically looking at its ability to help children lose weight and monitoring for side effects. Participants were randomized to receive either liraglutide or placebo, administered as a daily injection.
What this means
The primary completion of the SCALE KIDS trial signifies that data collection for the study's main objectives regarding liraglutide's effect on weight loss in children with obesity has concluded. While specific efficacy and safety results are not yet available, this milestone brings the trial closer to potential data readout. The findings from this study could inform future treatment guidelines for pediatric obesity, potentially expanding the therapeutic options beyond those currently available for adults.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The study record for NCT04775082, titled "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity", was updated on 2023-08-01 on clinicaltrials.gov.